News
AVDL
10.31
+1.98%
0.20
Leerink Partners Remains a Buy on Avadel Pharmaceuticals (AVDL)
TipRanks · 5d ago
Insider Purchase: Chief Financial Officer of $AVDL (AVDL) Buys 2,300 Shares
Barchart · 6d ago
Weekly Report: what happened at AVDL last week (1209-1213)?
Weekly Report · 12/16 10:10
Insider Purchase: Chief Financial Officer of $AVDL (AVDL) Buys 5,000 Shares
Barchart · 12/12 16:20
Avadel Pharmaceuticals announces publication of findings on sodium oxybate
TipRanks · 12/11 13:21
Avadel Pharmaceuticals Presents Results From Social Listening Analysis And Survey Of People With Narcolepsy Uncover Real-Life Challenges With Twice-Nightly Oxybate Therapy; Findings Published In 'Brain Sciences' Showed Missed Doses And Potential For Injury When Waking To Take A Second Dose Among The Key Challenges
Benzinga · 12/11 13:17
Insider Purchase: Chief Executive Officer of $AVDL (AVDL) Buys 402 Shares
Barchart · 12/11 03:46
Insider Purchase: Director at $AVDL (AVDL) Buys 10,075 Shares
Barchart · 12/11 03:30
Insider Purchase: Director at $AVDL (AVDL) Buys 3,000 Shares
Barchart · 12/10 16:18
Weekly Report: what happened at AVDL last week (1202-1206)?
Weekly Report · 12/09 10:09
Tuesday's ETF with Unusual Volume: FYC
NASDAQ · 12/03 18:11
Avadel chief commercial officer resigns, stock down 14%
Seeking Alpha · 12/03 15:45
Weekly Report: what happened at AVDL last week (1125-1129)?
Weekly Report · 12/02 10:09
Axsome: Focus On AXS-12 Targeting Narcolepsy, Which Just Released Positive Data
Seeking Alpha · 11/29 15:32
Weekly Report: what happened at AVDL last week (1118-1122)?
Weekly Report · 11/25 10:05
Avadel Pharmaceuticals: Despite My Sympathies For The Company, Stock Looks Risky
Seeking Alpha · 11/22 18:59
Weekly Report: what happened at AVDL last week (1111-1115)?
Weekly Report · 11/18 10:04
Strong Performance and Positive Outlook Drive Buy Rating for Avadel Pharmaceuticals
TipRanks · 11/14 07:46
Avadel Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 11/13 13:31
Avadel Pharmaceuticals Price Target Cut to $25.00/Share From $27.00 by HC Wainwright & Co.
Dow Jones · 11/13 13:31
More
Webull provides a variety of real-time AVDL stock news. You can receive the latest news about Avadel Pharmaceu through multiple platforms. This information may help you make smarter investment decisions.
About AVDL
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME and MEDUSA. Its MICROPUMP technology allows for the development of modified release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.